NCT01701349撤回3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)
Mateon Therapeutics0 个研究点开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- Overall survival
研究概览
简要总结
This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.
详细描述
The Treatment Plan followed for all subjects will consist of:
- A Screening Visit within 14 days before study drug (fosbretabulin or placebo) administration
- A Treatment Phase of 21-day combination treatment (study drug plus chemotherapy) cycles (up to 6 cycles)
- An End of Treatment Phase assessment
- An End of Study Visit occurring 30 days after the last day of study drug administration, as able
After the last clinic visit, all subjects will be followed for survival by monthly phone calls, email, or in-person.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable, residual, recurrent or persistent ATC, histologically or cytologically confirmed
- •Prior cytotoxic therapeutic regimen as primary therapy for curative intent or prior targeted therapies (TKIs) are eligible (Prior taxane or platinum therapy is allowed)
- •Untreated ATC following biopsy, surgery for curative intent, palliation, or after radiation therapy has been considered or administered with or without radiosensitizing chemotherapy
- •Disease present on clinical exam (measurable or non-measurable)
- •Distant metastases (Stage IVC) only must have histologic confirmation of ATC either from the original primary lesion or a metastatic site
- •Neoadjuvant therapy with radiation and either radiosensitizing chemotherapy followed by surgery for curative intent, palliation, or biopsy are eligible if residual or persistent ATC is present
- •Subjects with tracheostomy are eligible
- •ECOG PS 2 or less
- •Adequate bone marrow, renal, and hepatic function, electrolytes WNL for the institution
排除标准
- •Disease that is able to be completely resected with negative microscopic margins and without any residual disease in the body
- •Active brain metastases, including symptomatic involvement, evidence of cerebral edema by prior CT or MRI, radiographic evidence of brain metastasis since definitive therapy, or continued requirement for corticosteroids for cerebral edema
- •History of malignancies other than ACT except prior lower grade thyroid malignancy, curatively treated basal cell carcinoma and in-situ melanoma of the skin, cervical intra-epithelial neoplasia,localized prostate cancer, in-situ carcinoma of the breast
- •Known intolerance or hypersensitivity to fosbretabulin, paclitaxel, carboplatin or any of their components
- •Receiving concurrent investigational therapy or have received investigational therapy for any indication within 28 days of the first scheduled day of dosing
- •Grade 3 or greater peripheral neuropathy
- •History of prior cerebrovascular event,including transient ischemic attack within the past 6 months
- •Uncontrolled hypertension defined as blood pressure >150/100 mm Hg despite medication
- •Symptomatic vascular disease (e.g. intermittent claudication)
- •History of unstable angina pectoris pattern, myocardial infarction (including non-Q wave) within the past 6 months, or NYHA Class III or IV congestive heart failure
- •History of torsade de pointes, ventricular tachycardia, ventricular fibrillation or congenital long QT syndrome.
- •Pathologic bradycardia (<60 b/m or heart block(excluding 1st degree block, consisting of PR interval prolongation only)
- •ECG findings of clinically significant ventricular arrhythmia, new ST segment elevation or depression, or new Q wave on ECG (PVCs are not excluded).
- •QTc interval 480 ms or more
- •Requirement of concurrent treatment with any drugs know to prolong the QTc interval, including anti-arrhythmic medications
- •Potassium and/or magnesium concentrations below normal range for the reference laboratory
- •History of solid organ or bone marrow transplant
研究组 & 干预措施
Fosbretabulin + paclitaxel + carboplatin
Active Comparator
Six 21 day cycles of:
Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2
干预措施: Fosbretabulin + paclitaxel + carboplatin (Drug)
Placebo + paclitaxel + carboplatin
Placebo Comparator
Six 21-day cycles of:
Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2
干预措施: Placebo + paclitaxel + carboplatin (Drug)
结局指标
主要结局
Overall survival
时间窗: Maximun length of study for each subject is 2 years from date of randomization
次要结局
- Number of adverse events of the combination of fosbretabulin + paclitaxel + carboplatin(Maximun length of study for each subject is 2 years from date of randomization)
- Number of participants with 1-year survival(Maximun length of study for each subject is 2 years from date of randomization)
研究者
相似试验
已完成
3 期
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisDermatomyositisNCT05437263Priovant Therapeutics, Inc.241
终止
3 期
Voxelotor Neurocognitive Function StudySickle Cell DiseaseNCT05228834Pfizer1
已完成
3 期
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)Disease, HodgkinNCT01100502Seagen Inc.329
终止
3 期
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial FibrillationParoxysmal Atrial FibrillationNCT05039359InCarda Therapeutics, Inc.54
进行中（未招募）
3 期
A Study of IBI362 9 mg in Chinese Adults With ObesityObesityNCT06164873Innovent Biologics (Suzhou) Co. Ltd.462